BioLineRx has dosed the first subject in the Phase I clinical trial of its CXCR4 inhibitor, motixafortide, for CD34+ hematopoietic stem cell (HSC) mobilisation for gene therapies in sickle cell disease (SCD).

The trial will analyse motixafortide as a single agent and along with natalizumab as new regimens to aid in mobilising CD34+ hematopoietic stem cells.

It will enrol five adult SCD patients who are currently receiving automated red blood cell exchanges through apheresis.

Analysing the safety and tolerability of motixafortide monotherapy and along with natalizumab, defined by dose-limiting toxicities, will be the primary objective of the trial.

Detecting the number of CD34+ hematopoietic stem and progenitor cells (HSPCs) mobilised through leukapheresis as well as the kinetics of CD34+ HSPC mobilisation to peripheral blood following the treatment comprise the secondary objectives.

BioLineRx is carrying out the trial in partnership with Washington University School of Medicine in St Louis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The company anticipates reporting the preliminary findings from the trial in the second half of next year.

BioLineRx chief development officer Ella Sorani said: “The recent FDA approvals of two gene therapies for sickle cell disease in the US is an exciting development for the sickle cell community, and we are eager to advance clinical research of motixafortide that may potentially lead to additional CD34+ hematopoietic stem cell mobilisation options in the future for patients with this condition.”

In September this year, motixafortide received US Food and Drug Administration approval for use along with filgrastim (G-CSF) for mobilising HSCs for collection and autologous transplantation in multiple myeloma patients.

It is indicated for usage under the brand name Aphexda.

In April this year, the company reported data from the Phase lll GENESIS trial of motixafortide plus G-CSF for mobilising HSCs to treat multiple myeloma patients before autologous stem cell transplantation.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.